<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03478033</url>
  </required_header>
  <id_info>
    <org_study_id>2017ZX10202101-002</org_study_id>
    <nct_id>NCT03478033</nct_id>
  </id_info>
  <brief_title>Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</brief_title>
  <acronym>RRHT</acronym>
  <official_title>The Efficacy and Safety Evaluation of Standardized Treatment Included Rifampicin or Rifabutin in HIV/AIDs Patients Combined With Pulmonary Tuberculosis. A Prospective Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Guangxi Zhuang Autonomous Region Longtan hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Fourth People's Hospital of Nanning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Third People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yunnan Provincial Infectious Disease Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chongqing Public Health Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Public Health Clinical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compared the efficacy and safety of rifampicin and rifabutin which included in the&#xD;
      standard treatment of anti-tuberculosis in HIV/AIDs patients combined with pulmonary&#xD;
      tuberculosis, a multi-center, prospective cohort will be established. Antiviral efficacy and&#xD;
      drug drug interaction will be investigated in order to provide optimized treatment for&#xD;
      HIV/AIDs with tuberculosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two hundreds and thirty participants will be randomly assigned to receive an&#xD;
      anti--tuberculosis treatment include rifampicin or rifabutin for two months of intensive&#xD;
      therapy. Isoniazid and rifampicin (or rifabutin) will be continued to use for four months of&#xD;
      consolidation therapy. A total of followed up period will be 12 months.&#xD;
&#xD;
      The antiretroviral therapy（ART） include:&#xD;
&#xD;
      Tenofovir disoproxil fumarate 300mg/d +Lamivudine 300mg/d+ Efavirenz 600mg/d; or Zidovudine&#xD;
      300mg bid +Lamivudine 300mg/d +Efavirenz 600mg/d.&#xD;
&#xD;
      ART will be started after 2 weeks of anti-tuberculosis.&#xD;
&#xD;
      The follow-up visits include 2th, 4th, 6th, 8th, 12th,16th, 20th, 24th, 32th, 36th, 40th,&#xD;
      44th and 48th week. sputum smear, sputum culture, chest X-ray, CD4 Lymphocyte counts,HIV&#xD;
      viral load and adverse event will be tested and recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 15, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participates are assigned to one of two groups in parallel for the duration of the study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of sputum negative conversion</measure>
    <time_frame>2~24 weeks</time_frame>
    <description>The rate of the patients whose mycobacterium tuberculosis cannot be detected in sputum smear or bacteria culture.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Case fatality rate</measure>
    <time_frame>12 months</time_frame>
    <description>The number of deaths during follow-up caused by HIV/AIDS and TB / the number of patients with HIV/AIDs and TB enrolled in this study * 100%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment completion status</measure>
    <time_frame>12 months</time_frame>
    <description>The rate of patients who complete the whole anti-tuberculous treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of HIV viral load less than the detection limit</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>The percentage of HIV viral load less than the detection limit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>12 months</time_frame>
    <description>The number and severity of adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of sputum negative conversion</measure>
    <time_frame>2~24 weeks</time_frame>
    <description>The time of sputum negative conversion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest CT scans improvement</measure>
    <time_frame>2~24 weeks</time_frame>
    <description>Chest CT showed tuberculosis lesion absorption</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Tuberculosis, Pulmonary</condition>
  <condition>AIDS</condition>
  <arm_group>
    <arm_group_label>Rifampicin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rifampicin group: Intensive treatment（4 types of anti-TB medicines）for 2 months, then isoniazid and rifampicin for 4 months of consolidation therapy.&#xD;
isoniazid: 10-15mg/kg rifampicin: 10-20mg/kg pyrazinamide: 30-40mg/kg thambutol: 0.75(W&lt;50kg)；1.0 g/d（W≥50kg）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifabutin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifabutin group: Intensive treatment（4 types anti-TB medicines）for 2 months,then isoniazid and rifabutin for 4 months of consolidation therapy.&#xD;
isoniazid: 10-15mg/kg rifabutin: 0.45g/d(W&lt;50kg); 0.6g/d( W≥50kg） pyrazinamide: 30-40mg/kg thambutol: 0.75(W&lt;50kg)；1.0 g/d（W≥50kg）</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <description>Rifampicin capsules, 150mg</description>
    <arm_group_label>Rifampicin group</arm_group_label>
    <other_name>Rifampicin/INH/EMB/PZA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifabutin</intervention_name>
    <description>Rifabutin capsules, 150mg</description>
    <arm_group_label>Rifabutin group</arm_group_label>
    <other_name>Rifabutin/INH/EMB/PZA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 18-65 years old;&#xD;
&#xD;
          2. No limited to gender;&#xD;
&#xD;
          3. If anti-HIV-1 positive samples are detected by an initial test based on the ELISA&#xD;
             method, they should be confirmed by western blot;&#xD;
&#xD;
          4. The patients who are diagnosed with pulmonary TB (mycobacterium tuberculosis of sputum&#xD;
             smear or culture was positive) but had never be treated;&#xD;
&#xD;
          5. Sign informed consent form voluntarily, and guarantee to attend follow-up visits;&#xD;
&#xD;
          6. Do not have plan to remove from the current experimental site during the trial&#xD;
             process;&#xD;
&#xD;
          7. The patients do not receive any antiretroviral treatment before;&#xD;
&#xD;
          8. The overall situation of the patient should not affect the assessment and completion&#xD;
             of the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with acute infection;&#xD;
&#xD;
          2. During the screening period，patients with combined opportunistic infections and&#xD;
             instability (National HIV/AIDS treatment guidelines) except for tuberculosis, or&#xD;
             combined malignancy;&#xD;
&#xD;
          3. During the screening period，hemachrome &lt; 6 g/dl, leukocyte &lt; 2000 /µl, neutrophils &lt;&#xD;
             1000 /µl, platelet count &lt; 75000 /µl, blood amylase is greater than two times the&#xD;
             upper limit of normal, Scr is greater than1.5 times the upper limit of normal,&#xD;
             AST/ALT/AKP is greater than two times the upper limit of normal, TBIL is greater than&#xD;
             two times the upper limit of normal, serum CK is greater than two times the upper&#xD;
             limit of normal;&#xD;
&#xD;
          4. Now suffering from acute or chronic pancreatitis;&#xD;
&#xD;
          5. Now suffering from peripheral neuritis;&#xD;
&#xD;
          6. Pregnant and lactating women;&#xD;
&#xD;
          7. Patients with severe mental and neurological diseases;&#xD;
&#xD;
          8. Drug users；&#xD;
&#xD;
          9. Patients with history of heavy drinking and cannot be terminated;&#xD;
&#xD;
         10. Serious gastrointestinal ulcers；&#xD;
&#xD;
         11. Atherosclerosis affects the arteries in the heart, brain or kidneys；&#xD;
&#xD;
         12. Non-Chinese nationality；&#xD;
&#xD;
         13. Now suffering from myopathy；&#xD;
&#xD;
         14. Patients with previously treated tuberculosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongzhou Lu, PhD，MD</last_name>
    <phone>86-021-37990333</phone>
    <phone_ext>3222</phone_ext>
    <email>luhongzhou@fudan.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingzhong Shen, PhD，MD</last_name>
      <phone>86-021-37990333</phone>
      <phone_ext>3222</phone_ext>
      <email>027465@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>March 20, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Public Health Clinical Center</investigator_affiliation>
    <investigator_full_name>Hongzhou Lu</investigator_full_name>
    <investigator_title>vice director</investigator_title>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>AIDS</keyword>
  <keyword>Rifampicin</keyword>
  <keyword>Rifabutin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Rifabutin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

